Insilico Medicine Nominates Inhaled Preclinical Candidate for First AI-Discovered IPF Drug
Insilico Medicine, a clinical-stage AI drug discovery company, has announced the nomination of a preclinical candidate for an inhaled solution of ISM001–055, the first anti-fibrotic small molecule inhibitor for Idiopathic Pulmonary Fibrosis (IPF) developed using Insilico’s proprietary generative AI platform.
The inhaled solution offers potential advantages including a lower effective dose, wider safety margins, and reduced side effects compared to conventional oral or injected formulations. Preclinical studies demonstrated the inhaled ISM001–055 solution was well-tolerated with favorable efficacy, safety, and pharmacokinetic profiles.
IPF is a chronic and progressive lung disease characterized by irreversible scarring of lung tissue. The inhaled route allows direct delivery of the drug to the target organ while minimizing systemic exposure. Insilico aims to be the first AI-powered drug discovery company to advance an inhaled therapy into clinical trials.
“We are thrilled to see the nomination of an inhalation solution for our first AI-discovered drug candidate ISM001–055. This represents a major milestone, as over 99% of drug development programs fail at the preclinical stage,” said Insilico CEO Alex Zhavoronkov.
Powered by Insilico’s proprietary end-to-end AI platform Pharma.AI, the company now has over 30 pipeline programs spanning 29 targets, with 3 programs currently in clinical-stage human testing. The pipeline was generated using AI techniques for novel target discovery, molecular generation, and clinical trial simulation.
“At Insilico, we are continuously innovating and validating our AI capabilities across multiple disease areas, formulations, and routes of administration,” said Insilico Co-CEO Feng Ren. “We hope to advance this inhaled therapy into the clinic as soon as possible to address urgent unmet needs in IPF.”
The nomination of an inhaled preclinical candidate represents a significant achievement for AI-driven drug discovery. Insilico’s integrated AI approaches have the potential to rapidly develop novel therapeutics with optimized delivery methods. The company’s expanding clinical pipeline continues to demonstrate the power of artificial intelligence in innovating the end-to-end drug discovery process.
As Insilico Medicine’s achievements highlight, artificial intelligence has the potential to profoundly transform every stage of the drug discovery and development pipeline.
For pharmaceutical companies looking to embrace digital transformation and leverage AI, HAAMI INDUSTRY provides full-stack AI services specialized for the biopharma industry. With expertise across generative chemistry, computational biology, real-world data analysis, and clinical trial simulation, HAAMI INDUSTRY enables pharmaceutical leaders to integrate advanced AI throughout their workflows.
By partnering with HAAMI INDUSTRY for AI strategy and implementation, biopharma companies can accelerate innovation, optimize R&D, reduce costs, and bring life-changing therapies to market faster.
